Literature DB >> 24135225

Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25.

Hongzi Liang1, Leo Studach2, Ronald L Hullinger3, Jun Xie4, Ourania M Andrisani5.   

Abstract

Clinically aggressive prostate cancer (PCa) is linked to androgen resistance, metastasis, and expression of neuroendocrine markers. To understand mechanism(s) of neuroendocrine differentiation (NED) of PCa epithelia, we compared neuronal differentiation occurring during embryogenesis, in primary cultures of neural crest (NC) cells, and NED in PCa cell lines (LNCaP and PC3). We demonstrate, hypoxia promotes neuronal and neuroendocrine differentiation of NC cells and PCa cells, respectively, by inducing the miR-106 b~25 cluster. In turn, miR-106b~25 comprised of miR-106b, miR-93 and miR-25, down-regulates the transcriptional repressor REST, which represses neuron-specific protein-coding and miRNA genes. In prostate tumors of high Gleason score (≥ 8), an inverse trend was observed between REST and miR-106b~25 induction. Employing miRNA PCR arrays, we identified miRNAs up-regulated by hypoxia in LNCaP cells and REST-knockdown in NC cells. Significantly, a subset of miRNAs (miR-9, miR-25, miR-30d and miR302b) is up-regulated in high Gleason score (≥ 8) PCa, suggesting a mechanism by which NED contributes to PCa malignancy. We propose that loss of REST and induction of this set of microRNAs can serve as potential novel clinical markers of advanced PCa.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hypoxia; MicroRNAs; Neural crest cell differentiation; Neuroendocrine differentiation (NED); Prostate cancer; RE-1 silencing transcription factor (REST)

Mesh:

Substances:

Year:  2013        PMID: 24135225      PMCID: PMC3947575          DOI: 10.1016/j.yexcr.2013.09.020

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  48 in total

Review 1.  The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.

Authors:  A Mosca; A Berruti; L Russo; M Torta; L Dogliotti
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

2.  Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.

Authors:  Laura Poliseno; Leonardo Salmena; Luisa Riccardi; Alessandro Fornari; Min Sup Song; Robin M Hobbs; Paolo Sportoletti; Shorheh Varmeh; Ainara Egia; Giuseppe Fedele; Lucia Rameh; Massimo Loda; Pier Paolo Pandolfi
Journal:  Sci Signal       Date:  2010-04-13       Impact factor: 8.192

3.  miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.

Authors:  Avital Gaziel-Sovran; Miguel F Segura; Raffaella Di Micco; Mary K Collins; Douglas Hanniford; Eleazar Vega-Saenz de Miera; John F Rakus; John F Dankert; Shulian Shang; Robert S Kerbel; Nina Bhardwaj; Yongzhao Shao; Farbod Darvishian; Jiri Zavadil; Adrian Erlebacher; Lara K Mahal; Iman Osman; Eva Hernando
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

4.  CtBP2 downregulation during neural crest specification induces expression of Mitf and REST, resulting in melanocyte differentiation and sympathoadrenal lineage suppression.

Authors:  Hongzi Liang; Donna M Fekete; Ourania M Andrisani
Journal:  Mol Cell Biol       Date:  2011-01-03       Impact factor: 4.272

5.  Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen.

Authors:  L Studer; M Csete; S H Lee; N Kabbani; J Walikonis; B Wold; R McKay
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

Review 6.  [Breast carcinoma with predominant neuroendocrine differentiation].

Authors:  Sophie Frachon; Dominique Pasquier; Isabelle Treilleux; Daniel Seigneurin; François Ringeisen; Patrick Rosier; Michel Bolla; Jean Boutonnat
Journal:  Ann Pathol       Date:  2004-06       Impact factor: 0.407

7.  Large-scale expression analysis reveals distinct microRNA profiles at different stages of human neurodevelopment.

Authors:  Brandon Smith; Julie Treadwell; Dongling Zhang; Dao Ly; Iain McKinnell; P Roy Walker; Marianna Sikorska
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

8.  Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.

Authors:  Simona Nanni; Valentina Benvenuti; Annalisa Grasselli; Carmen Priolo; Aurora Aiello; Stefania Mattiussi; Claudia Colussi; Vittoria Lirangi; Barbara Illi; Manuela D'Eletto; Anna Maria Cianciulli; Michele Gallucci; Piero De Carli; Steno Sentinelli; Marcella Mottolese; Paolo Carlini; Lidia Strigari; Stephen Finn; Elke Mueller; Giorgio Arcangeli; Carlo Gaetano; Maurizio C Capogrossi; Raffaele Perrone Donnorso; Silvia Bacchetti; Ada Sacchi; Alfredo Pontecorvi; Massimo Loda; Antonella Farsetti
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

9.  Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.

Authors:  Stéphane Culine; Mounira El Demery; Pierre-Jean Lamy; François Iborra; Christophe Avancès; Frédéric Pinguet
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

10.  Involvement of bone morphogenetic protein-4 and bone morphogenetic protein-7 in the differentiation of the adrenergic phenotype in developing sympathetic neurons.

Authors:  E Reissmann; U Ernsberger; P H Francis-West; D Rueger; P M Brickell; H Rohrer
Journal:  Development       Date:  1996-07       Impact factor: 6.868

View more
  36 in total

Review 1.  The roles of microRNAs in the progression of castration-resistant prostate cancer.

Authors:  Satoko Kojima; Yusuke Goto; Yukio Naya
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

Review 2.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

3.  SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.

Authors:  Xiaotun Zhang; Ilsa M Coleman; Lisha G Brown; Lawrence D True; Lori Kollath; Jared M Lucas; Hung-Ming Lam; Ruth Dumpit; Eva Corey; Lisly Chéry; Bryce Lakely; Celestia S Higano; Bruce Montgomery; Martine Roudier; Paul H Lange; Peter S Nelson; Robert L Vessella; Colm Morrissey
Journal:  Clin Cancer Res       Date:  2015-06-12       Impact factor: 12.531

4.  Matrine induced G0/G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia (T-ALL) cells.

Authors:  Aslı Tetik Vardarlı; Zekeriya Düzgün; Ceren Erdem; Burçin Tezcanli Kaymaz; Zuhal Eroglu; Vildan Bozok Çetintas
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

Review 5.  miR-106b as an emerging therapeutic target in cancer.

Authors:  Surendra Kumar Sagar
Journal:  Genes Dis       Date:  2021-02-12

Review 6.  Selective repression of gene expression in neuropathic pain by the neuron-restrictive silencing factor/repressor element-1 silencing transcription (NRSF/REST).

Authors:  Dianna E Willis; Meng Wang; Elizabeth Brown; Lilah Fones; John W Cave
Journal:  Neurosci Lett       Date:  2015-12-08       Impact factor: 3.046

Review 7.  Neuroglobin Expression in the Brain: a Story of Tissue Homeostasis Preservation.

Authors:  Zoë P Van Acker; Evi Luyckx; Sylvia Dewilde
Journal:  Mol Neurobiol       Date:  2018-07-10       Impact factor: 5.590

8.  Phenethyl isothiocyanate (PEITC) suppresses prostate cancer cell invasion epigenetically through regulating microRNA-194.

Authors:  Chengyue Zhang; Limin Shu; Hyuck Kim; Tin Oo Khor; Renyi Wu; Wenji Li; Ah-Ng Tony Kong
Journal:  Mol Nutr Food Res       Date:  2016-05-17       Impact factor: 5.914

Review 9.  The many faces of neuroendocrine differentiation in prostate cancer progression.

Authors:  Stéphane Terry; Himisha Beltran
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

10.  miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.

Authors:  S J Seashols-Williams; W Budd; G C Clark; Q Wu; R Daniel; E Dragoescu; Z E Zehner
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.